Pearl Diagnostics, Inc.
Pearl Diagnostics is dedicated to transforming diagnostics for lung infections by developing innovative in vitro diagnostic tests that detect circulating microbial extracellular vesicles, providing early and non-invasive detection methods. The company collaborates with top institutions and has a leadership team with extensive expertise in infectious diseases, diagnostics, and clinical research. It aims to support healthcare providers with advanced diagnostic tools, focusing on fungal, bacterial, and other pathogen detection, with a strong emphasis on research, development, and regulatory approval processes.
Industries
Nr. of Employees
small (1-50)
Pearl Diagnostics, Inc.
Products
Urine-based ELISA kit for Aspergillus antigen detection (96-well)
A non-invasive urine antigen diagnostic kit implemented as a 96-well microplate ELISA intended to detect biomarkers of invasive pulmonary aspergillosis. Designed for laboratory workflows with ready-to-use reagents and a reported time-to-result of approximately three hours.
Urine-based ELISA kit for Aspergillus antigen detection (96-well)
A non-invasive urine antigen diagnostic kit implemented as a 96-well microplate ELISA intended to detect biomarkers of invasive pulmonary aspergillosis. Designed for laboratory workflows with ready-to-use reagents and a reported time-to-result of approximately three hours.
Services
Email and phone-based technical support, training materials and educational resources for diagnostic assay users.
Sales contact and product ordering information; site notes products are CE marked for Europe and not available in the US.
Email and phone-based technical support, training materials and educational resources for diagnostic assay users.
Sales contact and product ordering information; site notes products are CE marked for Europe and not available in the US.
Expertise Areas
- Urine-based diagnostics for pulmonary infections
- Immunoassay and monoclonal antibody development
- Point-of-care and high-throughput assay development
- Clinical validation and peer-reviewed publication
Key Technologies
- 96-well ELISA microplate assays
- Lateral flow / rapid immunoassays
- Monoclonal antibody antigen capture
- Extracellular vesicle detection assays
News & Updates
The WHO highlights the growing risk of deadly fungi, including Aspergillus fumigatus, Candida albicans, Candida auris, and Cryptococcus neoformans, emphasizing the need for urgent attention and improved diagnostics.
Pearl Diagnostics raised $3.5 million in seed funding to develop and commercialize a less invasive, faster urine antigen test for fungal pneumonia, targeting high-risk immunocompromised patients.
The company published a paper on urine antigen detection as an aid to diagnose invasive aspergillosis, in collaboration with Johns Hopkins University.
Pearl Diagnostics is working with partners to develop diagnostic tools for fungal infections, including aspergillosis, Candida auris, and Cryptococcus neoformans, which pose increasing health threats.
The European CE mark was granted, allowing for commercial sales of the Aspergillus urine assay in Europe.
The WHO highlights the growing risk of deadly fungi, including Aspergillus fumigatus, Candida albicans, Candida auris, and Cryptococcus neoformans, emphasizing the need for urgent attention and improved diagnostics.
Pearl Diagnostics raised $3.5 million in seed funding to develop and commercialize a less invasive, faster urine antigen test for fungal pneumonia, targeting high-risk immunocompromised patients.
The company published a paper on urine antigen detection as an aid to diagnose invasive aspergillosis, in collaboration with Johns Hopkins University.
Pearl Diagnostics is working with partners to develop diagnostic tools for fungal infections, including aspergillosis, Candida auris, and Cryptococcus neoformans, which pose increasing health threats.
The European CE mark was granted, allowing for commercial sales of the Aspergillus urine assay in Europe.